COMPASS Pathways Reports Full-Year 2025 Financial Results and Corporate Update

LONDON, March 24, 2026 – COMPASS Pathways plc (NASDAQ: CMPS), a leading biotechnology company developing psychedelic-inspired therapies, has announced its financial results for the year ended December 31, 2025, and provided an operational update that includes key financial and strategic developments.

Key Highlights from the Report

• Financial Results:
  • Cash Position: As of December 31, 2025, COMPASS Pathways reported cash and cash equivalents of \$149.6 million, compared to \$165.1 million at the end of 2024. The company’s total assets were \$210.3 million (down from \$213.7 million at the end of 2024).
  • R&D Expenses: Research and development expenses for Q4 2025 were \$29.9 million, a decrease from \$32.1 million in Q4 2024. This decrease was primarily due to reductions in personnel and non-cash share-based compensation following the company’s recent reorganization and associated lower staffing levels.
  • Net Loss: The company reported a net loss of \$179.0 million for the full year 2025, or \$(1.00) per share (basic and diluted), compared to a net loss of \$178.2 million or \$(3.08) per share in 2024. The significant net loss reflects ongoing investments in clinical trials and research programs.
  • Warrant Liabilities: The balance sheet shows a substantial increase in warrant liabilities—\$203.7 million as of December 31, 2025, compared to zero at the end of 2024. This change in the company’s capital structure could impact future dilution and is noteworthy for shareholders.
• Operational and Strategic Update:
  • The company is focused on advancing its clinical development programs, particularly its lead investigational therapy, COMP360 psilocybin treatment for treatment-resistant depression (TRD).
  • Management noted that the decrease in R&D spend was primarily due to a reorganization, signaling a shift in spending priorities and possibly a more streamlined operational approach going forward.

Shareholder Considerations & Potentially Price-Sensitive Information

• Cash Runway and Funding: With \$149.6 million in cash and equivalents at year end, investors should closely monitor the company’s cash runway, especially given the high R&D expense and net losses. The report signals the need for additional funding to meet future business goals, and any inability to secure such funding could force COMPASS Pathways to delay or scale back clinical programs.
• Warrant Liabilities: The sharp increase in warrant liabilities (\$203.7 million) introduces potential dilution risk for shareholders. If these warrants are exercised, the company could see a significant increase in shares outstanding, impacting EPS and potentially share value.
• Regulatory and Clinical Milestones: The company is preparing for key regulatory submissions, including a potential New Drug Application (NDA) for COMP360. However, management warns that the FDA may not agree with the company’s accelerated NDA submission plans, and any regulatory delays or setbacks could materially affect future prospects and share price.
• Forward-Looking Statements & Risks: The release includes numerous cautionary statements regarding uncertainties in clinical development, regulatory approval, and future funding needs. Investors are urged to consider these risks when evaluating the company’s forward trajectory.

Summary Table: Select Financial Data

Contact Information

• Media: Dana Sultan-Rothman ([email protected])
• Investors: Stephen Schultz ([email protected], +1 401 290 7324)

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties, including those detailed in COMPASS Pathways’ filings with the SEC. Actual results may differ materially from those indicated in forward-looking statements.

View COMPASS Pathways plc Historical chart here